Consumption of antibiotics and their possible relationship with bacterial resistance in the "Costa de Ponent" health region: Analysis of evolution through the initial and end periods of the last decade;Consumo de antibióticos y su posible relación con la resistencia bacteriana en la región sanitaria Costa de Ponent: Análisis evolutivo durante los períodos inicial y final de la última década

Atencion Primaria

Volumn 34, Issue 3, 2004, Pages 128-133

  Solé López, Júlia ^a,b   Rodriguez Palomar, G ^a   Grahit Vidosa, V ^a   Juncadella Garcia E ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b NONE   (Spain)

Author keywords

Antibiotic consumption; Bacterial resistance; Primary care

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFIXIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DEFINED DAILY DOSE; DRUG DOSE; DRUG USE; DRUG UTILIZATION; PRIMARY MEDICAL CARE; RANK SUM TEST; RETROSPECTIVE STUDY; SPAIN; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION REVIEW; HUMANS; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS;

EID: 4243129079     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064523     Document Type: Article

References (10)

1. Baquero F. A task force of the general direction for health planning of the spanish ministry of health. Antibiotic resistance in Spain: what can be done? Clin Infect Dis 1996;23:819-23.
2. Levy SB. Editorial response: antibiotic resistance worldwide: a Spanish Task Force responds. Clin Infect Dis 1996;23:824-6.
3. Bronzwaer S, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK, et al, and participants in the European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerging Infect Dis 2002;8:278-82.
4. Liñares J, Tubau F, Domínguez MA. Antibiotic resistance in Streptococcus pneumoniae in Spain: an overview in the 1990s. En: Tomasz A, editor. Streptococcus pneumoniae: molecular biology & mechanisms of disease. New York: Mary Ann Liebert Inc., 2000; p. 399-407.
5. Peña C, Albareda JM, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.
6. Millet FJ, Gracia S, Madridejos R, Solé J. Consumo de antibióticos (1993-1996) en la atención primaria de un área sanitaria con una tasa elevada de resistencias bacterianas. Aten Primaria 1998;21:451-7.
7. Anatomical Therapeutical Chemical Classification Index, with defined daily dosis (DDDs). Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1995.
8. LLop JC. Evolución en la utilización de antibacterianos en Cataluña. Impacto de los nuevos fármacos comercializados. Aten Primaria 1997;19:230-5.
9. Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (11979-1997). J Antimicrob Chemother 2000;46:767-73.
10. Ruiz Bremón A, Ruiz-Tovar M, Pérez Gorricho B, Díaz de Torres P, López Rodríguez R. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother 2000;45:395-400.